ARTICLES BY ANTONY HITCHCOCK
-
![Cell transfection with plasmid GettyImages-1290924802]( "Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's Why")
Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's Why11/19/2024The demand for plasmid DNA products is intrinsically linked to unique market conditions and funding environments. Here's what's driving them.
-
![GettyImages-2036497686-lab-team-collaboration-laboratory-tablet-computer]( "Have We Got Novel Drug Production And Compliance Timelines All Wrong?")
Have We Got Novel Drug Production And Compliance Timelines All Wrong?6/13/2024Drug developers might want to consider longer-term approaches to meeting manufacturing and regulatory requirements.
-
![GettyImages-1412962783]( "What Proposed Plasmid DNA Standards Say For GMP/Non-GMP Production")
What Proposed Plasmid DNA Standards Say For GMP/Non-GMP Production3/8/2024Today’s standards for plasmid DNA production lack specificity, and manufacturers have been clamoring for more. In late 2023, USP published draft General Chapter <1040> to help fill in the cracks.
Antony Hitchcock
Tony Hitchcock is the principal and owner of AGH Bioconsulting. He has spent his decades-long career in the in the biotechnology field, with over 30 years in the production of complex biologics for clinical trials in the European Union and U.S. He has worked in areas of process development and manufacturing with experience in engineering and process systems. He has worked on the development of more than 30 products for clinical trials, including plasmid DNA, viral and bacteriophage products, and recombinant proteins from microbial, mammalian, and insect cell sources. Contact him at tony@aghbioconsulting.com.